Amy Belt Raimundo

Founded in 2018, Abridge is the first AI-native clinician intelligence platform organized around the patient, built for clinicians, and designed to help health systems coordinate the clinical, financial, and evidence-based decisions for every moment of care. Powered by purpose-built AI for healthcare, Abridge connects patients, providers, payers, and life sciences companies. This year, the platform will support more than 100 million patient-clinician conversations across 300 of the largest and most complex health systems in the U.S. With deep EHR integration, Abridge’s automatic speech recognition and note generation has been validated to capture encounters in 28+ languages across specialties and care settings. Abridge is setting the industry standard for the responsible deployment of AI across health systems. Features like Linked Evidence map AI-generated clinical documentation to source data, helping clinicians quickly trust and verify the output. Abridge was awarded Best in KLAS for Ambient AI in 2025 and 2026, in addition to other accolades, including TIME Best Inventions of 2024 and 2025, CNBC Disruptor 2025, and Fast Company’s Most Innovative Companies 2025.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

Know what works. Make it better.™ NextHealth Technologies partners with health plans to provide rigorous, yet rapid evaluation of programs and initiatives that yield critical insights.

Our vision is a world where genomic information is fully accessible, understandable and integrated into health and well being. As a leading telegenetics care delivery company, we make genetic care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, we expand the reach and impact of genomic medicine. We help our partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre- and post-test genetic counseling through our team of expert genetic counselors, and personalized care plans. Our advisory services team uses an evidence-based approach to help partners evaluate and develop scalable, efficient and successful genetics programs.

Kona Medical, Inc., founded in 2009 and privately held, has developed an innovative and non-invasive therapy for the treatment of hypertension (high blood pressure) and other disorders. Kona Medical is based in Bellevue, Washington and is actively supported by leading medical technology investors. The flagship product, the Surround Sound® Hypertension Therapy System provides a one-time, non-invasive therapy for hypertension using ultrasound imaging to robotically guide the delivery of focused ultrasound energy for renal denervation (RDN). The procedure eliminates the need for radiation, contrast media, shielding or the Cath lab and reduces the cost and complexity of other technologies. Clinical trials have shown promise in significantly reducing blood pressure with this simple procedure and also provide an excellent safety profile. Note: Kona Medical’s technology is investigational and is not yet approved by the US Food and Drug Administration.

Founded in 2018, Abridge is the first AI-native clinician intelligence platform organized around the patient, built for clinicians, and designed to help health systems coordinate the clinical, financial, and evidence-based decisions for every moment of care. Powered by purpose-built AI for healthcare, Abridge connects patients, providers, payers, and life sciences companies. This year, the platform will support more than 100 million patient-clinician conversations across 300 of the largest and most complex health systems in the U.S. With deep EHR integration, Abridge’s automatic speech recognition and note generation has been validated to capture encounters in 28+ languages across specialties and care settings. Abridge is setting the industry standard for the responsible deployment of AI across health systems. Features like Linked Evidence map AI-generated clinical documentation to source data, helping clinicians quickly trust and verify the output. Abridge was awarded Best in KLAS for Ambient AI in 2025 and 2026, in addition to other accolades, including TIME Best Inventions of 2024 and 2025, CNBC Disruptor 2025, and Fast Company’s Most Innovative Companies 2025.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

At Gynesonics our mission is to design and develop new and advanced technologies for improving women’s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. If your post, comment or message references an adverse event with the Sonata Treatment, we may contact you for more information. To monitor the safety of our products, we encourage you to report suspected adverse effects by calling Gynesonics at 844-723-5382 Monday – Friday 9 AM – 5 PM EST. Alternatively, you can report any serious side effects directly to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088. We are committed to responding to your messages promptly. Our regular business hours are [Monday – Friday 9 AM – 5 PM EST. If a message is sent or a comment is made outside of regular business hours, or on weekends or company holidays, we will respond when business resumes. Please call 911 in the event of an emergency.

Know what works. Make it better.™ NextHealth Technologies partners with health plans to provide rigorous, yet rapid evaluation of programs and initiatives that yield critical insights.

Our vision is a world where genomic information is fully accessible, understandable and integrated into health and well being. As a leading telegenetics care delivery company, we make genetic care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, we expand the reach and impact of genomic medicine. We help our partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre- and post-test genetic counseling through our team of expert genetic counselors, and personalized care plans. Our advisory services team uses an evidence-based approach to help partners evaluate and develop scalable, efficient and successful genetics programs.